A GLP-1 weight loss medicine, semaglutide (Wegovy), has been approved by the FDA to treat MASH with moderate to advanced liver scarring
These are confusions that patients usually have
Patients can obtain it through legitimate medical channels with physician oversight, quality assurance, and ongoing monitoring
Tirzepatide is currently the only viable treatment option between these two dual receptor agonists, offering proven clinical results and established safety data
The more relevant question for older adults is muscle mass
Your provider will evaluate your symptoms, health history, and lifestyle factors to create a personalized plan that may include probiotic supplementation, dietary modifications, and hydration strategies